High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$7.8M
$7,751,968
Total Sells (Filtered)
$10.1M
$10,109,670
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
ZNTL
S
Zentalis Pharmaceuticals, Inc.
Vultaggio Vincent
• Officer • PAO and PFO
10b5-1 Sell
2026-02-10
$16,699
|
||||||
| ZNTL |
Zentalis Pharmaceuticals, Inc.
|
Officer • PAO and PFO
10b5-1 Sell
|
2026-02-10 | $16,699 | S | Form 4 |
|
ZNTL
S
Zentalis Pharmaceuticals, Inc.
Bruns Ingmar
• Officer • Chief Medical Officer
Sell to Cover
2026-02-09
$802
|
||||||
| ZNTL |
Zentalis Pharmaceuticals, Inc.
|
Officer • Chief Medical Officer
Sell to Cover
|
2026-02-09 | $802 | S | Form 4 |
| ZNTL |
Zentalis Pharmaceuticals, Inc.
|
CEO
Sell to Cover
|
2026-02-09 | $2,127 | S | Form 4 |
|
ZNTL
S
Zentalis Pharmaceuticals, Inc.
Vultaggio Vincent
• Officer • PAO and PFO
Sell to Cover
2026-02-09
$8,086
|
||||||
| ZNTL |
Zentalis Pharmaceuticals, Inc.
|
Officer • PAO and PFO
Sell to Cover
|
2026-02-09 | $8,086 | S | Form 4 |
|
ZNTL
S
Zentalis Pharmaceuticals, Inc.
Bruns Ingmar
• Officer • Chief Medical Officer
Sell to Cover
2026-02-06
$7,197
|
||||||
| ZNTL |
Zentalis Pharmaceuticals, Inc.
|
Officer • Chief Medical Officer
Sell to Cover
|
2026-02-06 | $7,197 | S | Form 4 |
| ZNTL |
Zentalis Pharmaceuticals, Inc.
|
CEO
Sell to Cover
|
2026-02-06 | $19,112 | S | Form 4 |
|
ZNTL
S
Zentalis Pharmaceuticals, Inc.
Vultaggio Vincent
• Officer • PAO and PFO
Sell to CoverΔOwn -16.0%
2026-02-06
$72,772
|
||||||
| ZNTL |
Zentalis Pharmaceuticals, Inc.
|
Officer • PAO and PFO
Sell to CoverΔOwn -16.0%
|
2026-02-06 | $72,772 | S | Form 4 |
|
ZNTL
S
Zentalis Pharmaceuticals, Inc.
Vultaggio Vincent
• Officer • PAO and PFO
10b5-1 Sell
2026-02-03
$1,398
|
||||||
| ZNTL |
Zentalis Pharmaceuticals, Inc.
|
Officer • PAO and PFO
10b5-1 Sell
|
2026-02-03 | $1,398 | S | Form 4 |
|
ZNTL
S
Zentalis Pharmaceuticals, Inc.
Vultaggio Vincent
• Officer • PAO and PFO
Sell to Cover
2026-02-02
$6,477
|
||||||
| ZNTL |
Zentalis Pharmaceuticals, Inc.
|
Officer • PAO and PFO
Sell to Cover
|
2026-02-02 | $6,477 | S | Form 4 |
|
ZNTL
P
Zentalis Pharmaceuticals, Inc.
WALTERS GROUP
• 10% Owner
Discretionary BuyΔOwn +91.6%
2025-12-31
$7,751,968Whale
|
||||||
| ZNTL |
Zentalis Pharmaceuticals, Inc.
|
10% Owner
Discretionary BuyΔOwn +91.6%
|
2025-12-31 | $7,751,968Whale | P | Form 4 |
|
ZNTL
S
Zentalis Pharmaceuticals, Inc.
Matrix Capital Management Company, LP
• 10% Owner
Discretionary SellΔOwn -53.7%
2025-12-15
$9,975,000Whale
|
||||||
| ZNTL |
Zentalis Pharmaceuticals, Inc.
|
10% Owner
Discretionary SellΔOwn -53.7%
|
2025-12-15 | $9,975,000Whale | S | Form 4 |